CeraSorb: Safely Eliminate Extra Surgery when handling Bone Grafting Procedures

Source: Curasan Inc.

A new study just released in a leading bone regeneration publication, Journal of Oral and Maxillofacial Implants (JOMI, Vol. 20, May/June 2005), confirms that Cerasorb pure-phase beta-tricalcium phosphate is a satisfactory graft material, even without autogenous bone, thereby
eliminating the need for surgeons to perform an extra surgery to harvest bone. 

Dr. Williams uses Cerasorb where indicated for his patients.

The study, which examined "whether donor site morbidity can be avoided  by
using synthetic bone substitutes," came to this conclusion:  "Comparisons with other studies reveal that beta-tricalcium phosphate (Cerasorb) is a satisfactory graft material, even without autogenous bone."  The  results of this two-year, multi-center, randomized clinical trial are critical,
because surgeons have generally believed that autogenous bone must be added to
improve results, regardless of the bone-substitute materials added. However, in order to add autogenous bone, a second operation has been required, putting "the patient at risk of donor site morbidity."  
 
The article, "A Prospective Multicenter Randomized Clinical Trial of Autogenous Bone versus beta-Tricalcium Phosphate Graft Alone for Bilateral Sinus Elevation: Histologic and Histomorphometric Evaluation," by  authors Gyorgy Szabo, MD, DDS, PhD; Luc Huys, DDS; Paul Coulthard, MD, DDS et  al, was based on research conducted at five prominent European centers,  with the
histological evaluations done blinded at a central location. 

To date, widely undifferentiated clinical experience has been gained with the vast range of bone augmentation materials stemming from various sources (bodies, animals, synthetic). This is the reason for which users have long demanded clinical studies comparing these materials directly with autogenous bone from patients, the so-called „gold standard“. Although bone graft substitutes have been in use for decades, so far competing manufacturers have shied this direct comparison.

Curasan is the first company to publish the desired data from this direct comparison. This two-year split-mouth study involved sinus lifting in 20 patients whereby Cerasorb® was used on one side and autogenous bone on the other. Cerasorb® achieved comparable clinical results. Harvesting autogenous bone often requires reentry surgery, which is stressful for the patient. In addition, Cerasorb® treatment is more economical. In total, this proves that Cerasorb® is superior to the gold standard
 

More About Cerasorb

Cerasorb® DENTAL, a new generation of bone regeneration material made from
pure-phase beta-tricalcium phosphate, is used primarily by periodontists and oral and maxillofacial surgeons for ridge augmentation, filling of extraction sites/bony defects, and repair of periodontal defects. Distributed in more than thirty countries, Cerasorb is marketed in the United States by Curasan Inc., a North Carolina-based subsidiary of Curasan AG, a world leader in regenerative medicine and dentistry.

In this day and age, no modern dentistry practice can completely shut itself off from implant medicine: advances in the development of systems and materials have been too great, and the successes too clear-cut for the issue to be avoided. In addition, patients' aesthetic and functional requirements have increased enormously. These requirements need to be met. Bone regeneration materials like CERASORB® make targeted bone regeneration possible; that is, they allow construction of a base on which implants can be positioned or further stabilized, such that long-term function is the expected outcome.

The full resorption over a defined period of time, with simultaneous transformation to autologous bone, is of particular significance in this respect.

Because of its rounded surface, CERASORB® is also remarkably tissue-friendly and thus particularly suitable for innovative procedures, such as so-called "internal sinus lift", since the risk of rupturing Schneider's membrane with this special surface is extremely low.

The choice of four particle sizes- the larger the defect to be filled, the bigger the particle size to be used -supports the overall concept.

CERASORB® is already intended for use in the following procedures:

Sinus lift
Bone splitting
Bone spreading
Other modern augmentative techniques
Combination with membrane